Pancreatic Cancer Epidemiology, Detection, and Management

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Zhang, Qiubo ^a   Zeng, Linjuan ^b   Chen, Yinting ^c   Lian, Guoda ^c   Qian, Chenchen ^c   Chen, Shaojie ^c   Li, Jiajia ^c   Huang, Kaihong ^c  

^a Lihuili Hospital of Ningbo Medical Center   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CALCYCLIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GROWTH DIFFERENTIATION FACTOR 15; IRINOTECAN; OSTEOPONTIN; OXALIPLATIN; PACLITAXEL; VITAMIN D;

ALCOHOL ABUSE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER THERAPY; CHEMORADIOTHERAPY; CHRONIC PANCREATITIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETES MELLITUS; ECONOMIC DEVELOPMENT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMAGE GUIDED RADIOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; REVIEW; SMOKING; TUMOR BIOPSY;

EID: 84958064164     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/8962321     Document Type: Review

References (38)

1. Y. Fang, Q. Yao, Z. Chen et al., "Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine," Medical Science Monitor, vol. 19, pp. 916-926, 2013.
2. IARC, GLOBOCAN 2012, http://globocan.iarc.fr.
3. T. Muniraj, P. A. Jamidar, and H. R. Aslanian, "Pancreatic cancer: a comprehensive review and update," Disease-a-Month, vol. 59, no. 11, pp. 368-402, 2013.
4. J. G. Treviño, S. Pillai, S. Kunigal et al., "Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma," Neoplasia, vol. 14, no. 12, pp. 1102-1114, 2012.
5. G. L. Matters, T. K. Cooper, C. O. McGovern et al., "Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat," Digestive Diseases and Sciences, vol. 59, no. 6, pp. 1180-1191, 2014.
6. A. T. Toriola, R. Stolzenberg-Solomon, L. Dalidowitz, D. Linehan, and G. Colditz, "Diabetes and pancreatic cancer survival: a prospective cohort-based study," British Journal of Cancer, vol. 111, no. 1, pp. 181-185, 2014.
7. S. Mizuno, Y. Nakai, H. Isayama et al., "Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in japanese patients," Pancreas, vol. 43, no. 7, pp. 1014-1017, 2014.
8. K. Chen, Q. Zhang, M. Peng, Y. Shen, P. Wan, and G. Xie, "Relationship between tea consumption and pancreatic cancer risk: a meta-analysis based on prospective cohort studies and case-control studies," European Journal of Cancer Prevention, vol. 23, no. 5, pp. 353-360, 2014.
9. A. B. Lowenfels, P. Maisonneuve, G. Cavallini et al., "Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group," The New England Journal of Medicine, vol. 328, pp. 1433-1437, 1993.
10. J. H. Liu and R. W. Rebar, "Endocrinology of pregnancy," in Maternal-Fetal Medicine: Principles and Practice, R. K. Creasy and R. Resnik, Eds., pp. 382-412, Saunders, Philadelphia, Pa, USA, 3rd edition, 2014.
11. L. Huang, C. Wu, D. Yu et al., "Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer," Carcinogenesis,vol.34, no.5, pp. 1001-1005, 2013.
12. S. T. Guo, C. C. Jiang, G. P. Wang et al., "MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer," Oncogene, vol. 32, no. 15, pp. 1910-1920, 2013.
13. A. P. Klein, "Identifying people at a high risk of developing pancreatic cancer," Nature Reviews Cancer, vol. 13, no. 1, pp. 66-74, 2013.
14. P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, "The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance," Immunological Reviews, vol. 222, no. 1, pp. 155-161, 2008.
15. G. Solinas, G. Germano, A. Mantovani, and P. Allavena, "Tumor-Associated Macrophages (TAM) as major players of the cancer-related inflammation," Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1065-1073, 2009.
16. H. Kurahara, H. Shinchi, Y. Mataki et al., "Significance of M2-polarized tumor-associated macrophage in pancreatic cancer," Journal of Surgical Research, vol. 167, no. 2, pp. e211-e219, 2011.
17. H. Kurahara, S. Takao, K. Maemura et al.,"M2-Polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pn0 pancreatic cancer," Pancreas, vol. 42, no. 1, pp. 155-159, 2013.
18. K. Yoshikawa, S. Mitsunaga, T. Kinoshita et al., "Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head," Cancer Science, vol. 103, no. 11, pp. 2012- 2020, 2012.
19. S. J. Chen, Q. B. Zhang, L. J. Zeng et al., "Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China," Current Oncology, vol. 22,no. 1, pp.e11-e19, 2015.
20. S. F. Schoppmann, P. Birner, J. Stöckl et al., "Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis," The American Journal of Pathology, vol. 161, no. 3, pp. 947-956, 2002.
21. R. Belbarka, Z. Fadoukheir, C. Delafouchardiere, F. Desseigne, and H. Errihani, "An unusual presentation of pancreatic cancer: muscular metastasis," Indian Journal of Cancer, vol. 51, no. 3, pp. 369-370, 2014.
22. I. Ninomiya, K. Yamazaki, K. Oyama et al., "Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells," Oncology Letters, vol. 8, no. 6, pp. 2709-2714, 2014.
23. J.-J. Li, H.-Y. Li, and F. Gu, "Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis," Genetic Testing and Molecular Biomarkers, vol. 18, no. 8, pp. 580-586, 2014.
24. X. Wang, Y. Li, H. Tian et al., "Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma," BMC Cancer, vol. 14, article 578, 2014.
25. M. Tobi, M. Kim, D. H. Weinstein et al., "Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma," Digestive Diseases and Sciences, vol. 58, no. 3, pp. 744-750, 2013.
26. H. E. Adamek, J. Albert, H. Breer, M. Weitz, D. Schilling, and J. F. Riemann, "Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study," The Lancet, vol. 356, no. 9225, pp. 190-193, 2000.
27. J. B. Klapman, R. Logrono, C. E. Dye, and I. Waxman, "Clinical impact of on-site cytopathology interpretation on endoscopic ultrasound-guided fine needle aspiration," American Journal of Gastroenterology, vol. 98, no. 6, pp. 1289-1294, 2003.
28. C. L. Wolfgang, J. M. Herman, D. A. Laheru et al., "Recent progress in pancreatic cancer," CA: A Cancer Journal for Clinicians, vol. 63, no. 5, pp. 318-348, 2013.
29. P. J. Shukla, G. Barreto, and S. V. Shrikhande, "The evolution of pancreatoduodenectomy," Hepato-Gastroenterology, vol. 58, no. 109, pp. 1409-1412, 2011.
30. W. Hartwig, T. Hackert, U. Hinz et al., "Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome," Annals of Surgery, vol. 250, no.1,pp. 81-87, 2009.
31. A. R. Sasson, J. P. Hoffman, E. A. Ross et al., "En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?" Journal of Gastrointestinal Surgery, vol. 6, no. 2, pp. 147-158, 2002.
32. A. Neesse, P. Michl, K. K. Frese et al., "Stromal biology and therapy in pancreatic cancer," Gut, vol. 60, no. 6, pp. 861-868, 2011.
33. T. Conroy, F. Desseigne, M. Ychou et al., "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer," The New England Journal of Medicine, vol. 364, no. 19, pp. 1817-1825, 2011.
34. K. K. Frese, A. Neesse, N. Cook et al., "Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer," Cancer Discovery, vol. 2, no. 3, pp. 260-269, 2012.
35. S. H. Son, J. H. Song, B. O. Choi et al., "The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer," Radiation Oncology, vol. 7, article 203, 2012.
36. A. Nishioka, Y. Ogawa, K. Miyatake et al., "Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer," Oncology Letters, vol. 8, no. 1, pp. 404-408, 2014.
37. K. C. Soares, L. Zheng, B. Edil, and E. M. Jaffee, "Vaccines for pancreatic cancer," Cancer Journal, vol. 18, no. 6, pp. 642-652, 2012.
38. J. Chapiro, S. Sur, L. J. Savic et al., "Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer," Clinical Cancer Research, vol. 20, no. 24, pp. 6406-6417, 2014.